MedTrace Logo

Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions

NCT01080365 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2010-09-06

No results posted yet for this study

Summary

Study comparing 2 formulations of bosutinib in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

SKI-606 (Bosutinib)

500 mg commercial formulation film coated tablet, administered once daily

DRUG

SKI-606 (Bosutinib)

500 mg (5 ×100 mg) phase 3 formulation film coated tablets, administered orally once daily

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01080365 on ClinicalTrials.gov